Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735884 | 1.00 | PARP10 (0.47) | PARP10MAOBSMN1; SMN2HDAC8ALKBH1 | |
| SCHEMBL6734481 | 1.00 | PARP10 (0.47) | PARP10MAOBSMN1; SMN2HDAC8ALKBH1 | |
| SCHEMBL14456120 | 0.92 | PARP10 (0.53) | PARP10MAOBSMN1; SMN2HDAC8ALKBH1 | |
| SCHEMBL14664397 | 0.90 | PARP10 (0.51) | PARP10MAOBSMN1; SMN2HDAC8ALKBH1 | |
| SCHEMBL14456118 | 0.89 | PARP10 (0.55) | PARP10MAOBSMN1; SMN2HDAC8ALKBH1 | |
| SCHEMBL13498482 | 0.87 | PARP10 (0.53) | PARP10MAOBSMN1; SMN2HDAC8ALKBH1 | |
| SCHEMBL13498487 | 0.82 | PARP10 (0.50) | PARP10MAOBSMN1; SMN2HDAC8ALKBH1 | |
| SCHEMBL13498488 | 0.82 | PARP10 (0.46) | PARP10MAOBSMN1; SMN2HDAC8ALKBH1 | |
| SCHEMBL12903697 | 0.82 | MAOB (0.47) | MAOB | |
| SCHEMBL21401729 | 0.80 | MEN1 (0.40) | PARP10SMN1; SMN2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080290034-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | PARP10 2300/4885MAOB 757/4885SMN1; SMN2 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.